Troriluzole Shows Potential to Treat Moderate Alzheimer’s in Phase 2/3 Trial, Monitoring Board Rules

Troriluzole Shows Potential to Treat Moderate Alzheimer’s in Phase 2/3 Trial, Monitoring Board Rules
Troriluzole, an investigational oral therapy by Biohaven, shows a potential to improve cognition and lessen brain volume loss, a sign of Alzheimer's disease progression, a board reviewing the ongoing Phase 2/3 trial decided. The trial successfully completed its interim futility analysis — meaning it can efficiently reach preset goals measuring benefit — and can continue treating patients toward that end, its independent Data Safety Monitoring Board found. "We believe that troriluzole is a promising potential therapy for people suffering from the devastating impact of Alzheimer's disease," Irfan Qureshi, vice president of neurology at Biohaven, said in a press release. "We are very excited that the T2 Protect AD Study, which recently completed enrollment, has now passed the interim futility analysis." Trigriluzole (BHV-4157) is a new compound precursor of riluzole — an approved amyotrophic lateral sclerosis (ALS) treatment — designed to regulate glutamate activity, one of the most abundant and important signaling molecules in the brain. Unusual sensitivity to glutamate — or excessively high levels of this molecule — can damage and kill nerve cells. Troriluzole acts by increasing the expression and function of EAAT2, a transporter that is used by brain cells to reabsorb glutamate, removing it from the synapse — the junction between two nerve cells that allows them to communicate. Preclinical studies in animal models and human brain tissue samples suggest its use improves brain cell response to glutamate, protecting them. The T2 Protect AD trial (NCT03605667) is a Phase 2/3, placebo-controlled study evaluating troriluzole’s safety and efficacy to treat cognitive symptoms and prevent brain volume loss, a sign of AD progression, in more
Subscribe or to access all post and page content.